Skip to main
CATX

CATX Stock Forecast & Price Target

CATX Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Perspective Therapeutics Inc demonstrates a strong potential for growth, supported by promising preliminary data indicating improved progression-free survival (PFS) outcomes in heavily pre-treated cancer patients utilizing a 3.0 mCi dose of their radiopharmaceutical product. The company's lead asset, VMT-α-NET, has shown compelling effectiveness in neuroendocrine tumors (NETs), a market with an opportunity exceeding $1 billion, and exhibits favorable activity in specific tumor types, indicating a broad therapeutic applicability. Additionally, the strategic deprioritization of competing programs enhances the competitive landscape for VMT-α-NET, as the company advances its regulatory development plans and prepares for forthcoming data releases that could further strengthen investor confidence.

Bears say

Perspective Therapeutics Inc faces significant risks that contribute to a negative outlook on its stock, primarily related to poorer-than-expected clinical data for its product candidates. The competitive landscape in the oncology market poses a long-term threat, as greater competition could materially affect the market potential and valuation of its proprietary treatments utilizing the alpha-emitting isotope Lead-212. Additionally, potential political, regulatory, or commercial hurdles may hinder the company's ability to secure favorable reimbursement and adoption of its products, further complicating its growth trajectory.

CATX has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Perspective Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Perspective Therapeutics Inc (CATX) Forecast

Analysts have given CATX a Strong Buy based on their latest research and market trends.

According to 8 analysts, CATX has a Strong Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Perspective Therapeutics Inc (CATX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.